Suppression of tumor growth by intratumoral injection of short hairpin RNA-expressing plasmid DNA targeting β-catenin or hypoxia-inducible factor 1α

Journal of Controlled Release

Volumn 116, Issue 1, 2006, Pages 90-95

  Takahashi, Yuki ^a   Nishikawa, Makiya ^a   Takakura, Yoshinobu ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Electroporation; Gene delivery; In vivo; Primary tumor; RNAi

Indexed keywords

CONTROLLED DRUG DELIVERY; DNA; DRUG PRODUCTS; GENE TRANSFER; RNA; TUMORS;

CYTOMETRIC ANALYSIS; ELECTROPORATION; IN VIVO; PRIMARY TUMORS;

ANIMAL CELL CULTURE;

BETA CATENIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PLASMID DNA; SHORT HAIRPIN RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL COUNT; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ELECTROPORATION; FLOW CYTOMETRY; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; IMMUNOASSAY; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN TUMOR; TUMOR GROWTH;

ANIMALS; ANNEXIN A5; APOPTOSIS; BETA CATENIN; DNA; ELECTROPORATION; FLOW CYTOMETRY; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOPLASMS; NUCLEIC ACID CONFORMATION; PLASMIDS; RNA INTERFERENCE; RNA, CATALYTIC; RNA, MESSENGER; TRANSFECTION;

EID: 33751208913     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2006.09.002     Document Type: Article

References (25)

1. Zamore P.D., Tuschl T., Sharp P.A., and Bartel D.P. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101 1 (2000) 25-33
2. Tuschl T., Zamore P.D., Lehmann R., Bartel D.P., and Sharp P.A. Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev. 13 24 (1999) 3191-3197
3. Hammond S.M., Bernstein E., Beach D., and Hannon G.J. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 404 6775 (2000) 293-296
4. Kobayashi N., Matsui Y., Kawase A., Hirata K., Miyagishi M., Taira K., Nishikawa M., and Takakura Y. Vector-based in vivo RNA interference: dose-and time-dependent suppression of transgene expression. J. Pharmacol. Exp. Ther. 308 2 (2004) 688-693
5. Matsui Y., Kobayashi N., Nishikawa M., and Takakura Y. Sequence-specific suppression of mdr1a/1b expression in mice via RNA interference. Pharm. Res. 22 12 (2005) 2091-2098
6. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 6836 (2001) 494-498
7. Caplen N.J., Parrish S., Imani F., Fire A., and Morgan R.A. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc. Natl. Acad. Sci. U. S. A. 98 17 (2001) 9742-9747 Electronic publication 2001 Jul 31
8. Milhavet O., Gary D.S., and Mattson M.P. RNA interference in biology and medicine. Pharmacol. Rev. 55 4 (2003) 629-648
9. Gong H., Liu C.M., Liu D.P., and Liang C.C. The role of small RNAs in human diseases: potential troublemaker and therapeutic tools. Med. Res. Rev. 25 3 (2005) 361-381
10. Rye P.D., and Stigbrand T. Interfering with cancer: a brief outline of advances in RNA interference in oncology. Tumour Biol. 25 5-6 (2004) 329-336
11. Izquierdo M. Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther. 12 3 (2005) 217-227
12. Bertrand J.R., Pottier M., Vekris A., Opolon P., Maksimenko A., and Malvy C. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem. Biophys. Res. Commun. 296 4 (2002) 1000-1004
13. Kretschmer-Kazemi Far R., and Sczakiel G. The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides. Nucleic Acids Res. 31 15 (2003) 4417-4424
14. Grunweller A., Wyszko E., Bieber B., Jahnel R., Erdmann V.A., and Kurreck J. Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res. 31 12 (2003) 3185-3193
15. Miyagishi M., Hayashi M., and Taira K. Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug Dev. 13 1 (2003) 1-7
16. Zeng Y., and Cullen B.R. RNA interference in human cells is restricted to the cytoplasm. RNA 8 7 (2002) 855-860
17. Stevenson M. Therapeutic potential of RNA interference. N. Engl. J. Med. 351 17 (2004) 1772-1777
18. Zender L., and Kubicka S. SiRNA based strategies for inhibition of apoptotic pathways in vivo-analytical and therapeutic implications. Apoptosis 9 1 (2004) 51-54
19. Takahashi Y., Nishikawa M., Kobayashi N., and Takakura Y. Gene silencing in primary and metastatic tumors by small interfering RNA delivery in mice: quantitative analysis using melanoma cells expressing firefly and sea pansy luciferases. J. Control. Release 105 3 (2005) 332-343
20. Nelson W.J., and Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303 5663 (2004) 1483-1487
21. Verma U.N., Surabhi R.M., Schmaltieg A., Becerra C., and Gaynor R.B. Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin. Cancer Res. 9 4 (2003) 1291-1300
22. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev., Cancer 3 10 (2003) 721-732
23. Sun X., Kanwar J.R., Leung E., Lehnert K., Wang D., and Krissansen G.W. Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther. 8 8 (2001) 638-645
24. Li L., Lin X., Staver M., Shoemaker A., Semizarov D., Fesik S.W., and Shen Y. Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res. 65 16 (2005) 7249-7258
25. Supino R. MTT assays. Methods Mol. Biol. 43 (1995) 137-149